BioPorto A/S (BIOPOR.CO)

2.0500 -0.0400 (-1.91%) 收市：04:59PM CEST

BioPorto A/S

Tuborg Havnevej 15, st.
Ground Floor
Hellerup 2900
Denmark
45 45 29 00 00
https://bioporto.com

版塊: Healthcare
行業: Diagnostics & Research
全職員工: 27

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Peter Moerch Eriksen B.B.A., BBA	Chief Executive Officer	292k	無	1960
Prof. Lars Otto Uttenthal	Chief Scientific Officer	無	無	無
Ms. Gry Husby Larsen	Executive VP & Chief Legal Officer	無	無	無
Ms. Jennifer Zonderman	SVP of Global Marketing & US Commercialization	無	無	無
Mr. Nis Kruse	Executive VP of Strategic Partnerships and GM of EMEA & APAC	無	無	無
Mr. Jeffrey N. Haas	President & CEO of BioPorto Inc.	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 DKK。

描述

BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was incorporated in 1917 and is based in Hellerup, Denmark.

公司管治

截至 2024年6月1日 止，BioPorto A/S 的 ISS 管治質素評分為 3。 Pillar 分數正在審核中：4；董事會：1；股東權利：1；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。